Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to -$1.0 million.

  • Cidara Therapeutics' Change in Accured Expenses rose 1909.61% to $63.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.2 million, marking a year-over-year increase of 1815.67%. This contributed to the annual value of -$1.0 million for FY2024, which is 111.26% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Change in Accured Expenses of -$1.0 million as of FY2024, which was down 111.26% from $8.9 million recorded in FY2023.
  • Cidara Therapeutics' 5-year Change in Accured Expenses high stood at $8.9 million for FY2023, and its period low was -$2.4 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is $1.8 million, with a median of -$1.0 million in 2024.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 116.93% in 2022, then surged by 474.78% in 2023.
  • Cidara Therapeutics' Change in Accured Expenses (Yearly) stood at $6.6 million in 2020, then crashed by 116.58% to -$1.1 million in 2021, then plummeted by 116.93% to -$2.4 million in 2022, then soared by 474.78% to $8.9 million in 2023, then plummeted by 111.26% to -$1.0 million in 2024.